ABSTRACT. We have cloned the arginine deiminase (ADI) gene from Mycoplasma hominis PG21 genomic DNA by polymerase chain reaction, and changed four TGA tryptophan codons (stop codon in E. coli) to TGG codons in the coding region by site-directed mutagenesis in order to express in E. coli. The recombinant ADI (rADI) was purified to apparent homogeneity by Ni-affinity chromatography after extraction from inclusion bodies followed by refolding. The rADI expressed in E. coli was estimated to be 50 kDa. Dimeric forms of rADI exerted enzymatic activity. We found that high concentration of potassium dihydrogenphosphate (PDP) and L-arginine addition in refolding reaction increases the enzyme activity. The specific activity of rADl was calculated as 0.618 U/mg. In addition, the enzyme activity of purified rADI remained for at least one month in 100 mM PDP solution (pH 6.5), but diminished within one week in 100 mM PDP solution (pH 7.4). Anti-tumor activity of the purified rADI was estimated to be 0.036 U/ml as 50% growth inhibitory activity against human melanoma cell line G-361. Arginine dehydrolysing mycoplasmas convert L-arginine into L-citrulline and ammonia by the arginine deiminase (ADI; EC 3.5.3.6) activity [1] . ADI gene of Mycoplasma hominis PG21 has been cloned in Escherichia coli by using plasmid pUC118 [7] . ADI has been shown to affect apoptosis and inhibit NO synthesis (i.e., anti-angiogenic effects), and exert effects against tumor necrosis factor- (TNF-) and neutralize endotoxin. [2, 6, 11, 16, 23, 27] . ADI has also been known to inhibit the growth of melanoma and hepatocellular carcinoma cells in vitro as well as in vivo [19, 20, 24, 26] . This anti-tumor activity of ADI has been attributed to the depletion of L-arginine, which is essential in these tumor cells [20, 25] . Normal cells are not sensitive to external addition of ADI since they produce L-arginine by themselves. Expression of the ADI gene of M. homins PG21 in E. coli has been hampered since the ADI gene of M. hominis has four opal nonsense codons, which are known to encode tryptophan in mycoplasma cells. We have changed these opal codons to universal tryptophan codons and successfully expressed the recombinant ADI (rADI) gene of M. homins in E. coli, and demonstrated the enzymatic activity of purified rADI.
Arginine dehydrolysing mycoplasmas convert L-arginine into L-citrulline and ammonia by the arginine deiminase (ADI; EC 3.5.3.6) activity [1] . ADI gene of Mycoplasma hominis PG21 has been cloned in Escherichia coli by using plasmid pUC118 [7] . ADI has been shown to affect apoptosis and inhibit NO synthesis (i.e., anti-angiogenic effects), and exert effects against tumor necrosis factor- (TNF-) and neutralize endotoxin. [2, 6, 11, 16, 23, 27] . ADI has also been known to inhibit the growth of melanoma and hepatocellular carcinoma cells in vitro as well as in vivo [19, 20, 24, 26] . This anti-tumor activity of ADI has been attributed to the depletion of L-arginine, which is essential in these tumor cells [20, 25] . Normal cells are not sensitive to external addition of ADI since they produce L-arginine by themselves. Expression of the ADI gene of M. homins PG21 in E. coli has been hampered since the ADI gene of M. hominis has four opal nonsense codons, which are known to encode tryptophan in mycoplasma cells. We have changed these opal codons to universal tryptophan codons and successfully expressed the recombinant ADI (rADI) gene of M. homins in E. coli, and demonstrated the enzymatic activity of purified rADI.
MATERIALS AND METHODS

Construction of ADI expression vector:
Four stop codons TGA in the ADI gene cloned in pUC118 was changed into TGG by site-directed mutagenesis mediated by DpnImethod in order to express in E. coli [21] . Correct introductions of the mutation were confirmed by DNA sequencing. The mutated ADI gene, designated as SYN1903, was recloned into pET-47b (Novagen, Darmstadt, Germany) expression vector.
Expression and purification of ADI: Recombinant pET47b plasmids encoding mycoplasmal ADI gene were transformed into competent E. coli BL21 (DE3) cells. The transformant was grown in 600 ml Luria broth (Sigma-Aldrich, St. Louis, MO, U.S.A.) at 30C, and isopropyl 1-thio--Dgalactoside was added at final concentration of 0.1 mM for induction of the recombinant protein when the OD 600 reached at 0.4. After an additional cultivation for 4 hr at 30C, the broth culture was centrifuged at 5,000  g for 10 min at 4C. The harvested cells were suspended in Bacterial Protein Extraction Reagent (B-PER) solution (Pierce Biotechnology, Inc., IL, U.S.A.). The homogenate was centrifuged at 15,000  g for 15 min at 4C, and the resulting pellets were further purified by using B-PER according to the manufacturer's instructions. Recombinant protein was expressed as inclusion bodies in E. coli. Inclusion bodies were dissolved in a denaturing buffer (50 mM Tris-hydrochloride (pH 8.5), 6 M guanidine-hydrochloride, and 10 mM dithiothreitol (DTT)) for 1 hr at 37C [14] . The dissolved proteins were refolded in a tenfold excess volume of 100 mM potassium dihydrogenphosphate (PDP) solution (pH 7.4) containing 100 mM L-arginine for 36 hr at 15C after removing cell debris by centrifugation. The renatured proteins were purified by HisTrap FF crude (GE Healthcare, Buckinghamshire, U.K.), and protein concentrations were determined with Protein Assay CBB solution (Nacalai tesque, Kyoto). The purified protein was then analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and was used for assay of enzymatic activity.
Immunoblotting analysis of the purified recombinant protein: The purified recombinant protein was boiled and separated on identical 10-20% gradient SDS-PAGE gels in duplicate under reducing condition. One of the gels was stained with Coomassie brilliant blue and the other was electrotransferred onto polyvinylidene difluoride (PVDF) membranes (Daiichi Chemicals, Tokyo, Japan) using an electroblotting apparatus (Daiichi Chemicals, Tokyo, Japan) at 15 volts for 30 min. The electroblotted membrane was stained in Ponceau S solution for 1 min, and washed with TTBS (Tris-buffered saline containing 0.05% Tween 20) for 10 min. The PVDF membrane was then soaked in blocking buffer consisting (1% bovine serum albumin, 1% Tween 20 in phosphate-buffered saline) for 60 min, and wash three times with TTBS. Thereafter, the membrane impregnated with the purified recombinant protein was incubated in blocking buffer containing a 1:10,000 dilution of rabbit immune serum against ADI at ambient temperature for 90 min. The immune serum was prepared by immunizing a male Kbl:JW SPF rabbit (Kitayama Labes, Nagano, Japan) with 2 mg of a synthetic oligo-peptide (CPGLVIGY-DRNEKTN), a possible epitope elucidated from the nucleic acid sequence of the ADI of M. hominis, conjugated with Maleimide (Pierce Biotechnology, Rockforf, IL, U.S.A.). After washing in TTBS, the membrane was incubated in blocking buffer containing a 1:2,000 dilution of alkaline phosphatase-conjugated goat anti-rabbit IgG antibody (Bethy Laboratories, Inc., Montgomery, AL, U.S.A.) and then rinsed with TTBS. The membrane was rinsed in copious volumes of distilled water, and the bound antibodies were detected by using the 1-Step TM NBT/BCIP (Thermo Scientific, Rockford, IL, U.S.A.) according to the manufacturer's instructions.
Enzymatic assay of recombinant ADI: The rADI activity was examined as described by Miyazaki et al. [15] . The reaction mixture is consisting of 100 mM PDP solution (pH6.5), 10 mM L-arginine and 0.1 ml enzyme solution in final volume of 1 ml, and was incubated at 37C for 30 min, after which the reaction was terminated by adding 1 ml of mixture of concentrated H 2 SO 4 and H 3 PO 4 at 1:3 (v/v). The amount of citrulline formed during the incubation was measured by observing colored reaction due to the product formed with diacetyl-mono-oxime by the method of Oginsky [18] . One unit (U) of ADI activity was defined as the amount of enzyme that converted 1 mol of L-arginine to 1 mol of L-citrulline every minute under the assay conditions.
Cell culture: Human melanome cell line G-361 (JCRB9074) was maintained in Dulbecco's modified Eagle's medium (DMEM) (Nissui) supplemented with 10% Hyclone fetal bovine serum (FBS) (Thermo Scientific, Rockford, IL, U.S.A.), 100 g/ml streptomycin, and 100 U/ ml penicillin at 37C in 5% CO 2 atmosphere.
In vitro assay for growth-inhibitory activity: Recombinant ADI was examined for its growth-inhibitory activity on the proliferation of G-361 cells. Briefly, G-361 cells were grown in DMEM supplemented with 10% FBS and incubated for 72 hr at 37C under 5% CO 2 . The test cells (1  10 4 per well) were dispensed in each well of 96-well microplates containing 100 l DMEM supplemented with 10% FBS. When G-361 cells were grown to 80% confluence, the medium was replaced with 100 l DMEM supplemented with 2% FBS and with the enzyme solutions containing 0.001, 0.0025, 0.005, 0.01, 0.025, and 0.05 U/ml sterilized by filtration and the microplates were further incubated at 37C for 72 hr in 5% CO 2 atmosphere. After 72 hr, 10 l of Cell Counting Kit-8 (Doujin Chemicals, Tokyo, Japan) was added into each well and mixed thoroughly. The cells in microplates were incubated at 37C for 4 hr in 5% CO 2 atmosphere, and absorbance at 450 nm was measured in an AROVO MX/Light microplate-reader (Perkin Elmer, Florida, U.S.A.).
RESULTS
SDS-PAGE and Western blot of the recombinant protein:
The purified recombinant protein fractionated on SDS-PAGE under reducing conditions revealed a single band at approximately 50 kDa. Native-PAGE analyses supported the notion that the original form of the rADI is a dimeric protein (data not shown). The recombinant protein prepared from inclusion bodies dissolved in guanidine hydrochloride solution depleted with DTT appeared as a dimeric protein by SDS-PAGE under non-reducing conditions, but lacked enzyme activity. These results suggest that the recombinant proteins in inclusion bodies form dimers by disulfide binding, but the rADI with enzymatic activity form dimers by another binding. A single band was demonstrated on the Western blot transferred from a gel under reducing condition by using a specific antiserum against ADI of M. hominis. Molecular mass of the band on the Western blot was estimated to be 50 kDa, suggesting that the band represented the rADI molecules (Fig. 1) .
Enzymatic activity of the recombinant ADI: The amount of citrulline formed during the reaction was measured by observing colored changes due to the products formed with diacetyl-mono-oxime by the method of Oginsky [18] . The specific activity of rADl was calculated as 0.618 U/mg, which was lower than that of crude protein of mycoplasmal ADI (Fig. 2) .
Conditions for refolding reaction: Refolding of the recombinant protein was examined in 100 mM PDP solution (pH 7.4) without L-arginine and in 10 mM PDP solution (pH 7.4) with 100 mM L-arginine. We found that 100 mM PDP solution (pH 7.4) containing L-arginine gave higher activity than 10 mM PDP solution (pH 7.4) with 100 mM Larginine or 100 mM PDP solution (pH 7.4) without L-arginine for the refolding reaction (Fig. 3) . The results suggest that high concentration of potassium and L-arginine addition increased the activity. The enzyme activity of purified rADI remained for at least one month in 100 mM PDP solution (pH 6.5), but diminished within one week in 100 mM PDP solution (pH 7.4).
In vitro growth-inhibitory activity: The in vitro growthinhibitory activity of ADI is shown in Fig. 4 . Cell lines were treated with ADI in a dose dependent manner. The ADI concentration required for 50% growth inhibition was estimated to be 0.036 U/ml for G-361. After 72 hr, cell growth was markedly inhibited by the ADI.
DISCUSSION
In this paper, we described an efficient method for the production of rADI in E. coli cells using a cloned ADI gene of M. hominis PG21. Mycoplasma hominis is a non-fermentative species that convert L-arginine into L-citrulline and ammonia by the ADI activity [1] . Arginine dehydrolysing mycoplasmas utilize L-arginine as a major non-glycolytic energy source [22] . Although L-arginine is non-essential nutrient for normal mammalian cells because they are able to synthesize L-arginine from L-citrulline through the arginosuccinase synthase and arginosuccinase lyase, some animal and human tumors lack these enzymes and require Larginine for growth. ADI derived from mycoplasmas has been reported to induce apoptosis in various human cancer cells in vitro as well as exert a potential anti-tumor activity in vivo [6, 10, 11, 26] . Mycoplasmal ADI has also been known as a suppressive factor against replication of human immunodeficiency virus (HIV) [12] . Therefore, ADI is considered as one of the promising candidates for cancer thera- peutics as well as anti-HIV drugs [4, 17] . Although a recombinant ADI has been prepared from several other microorganisms for this purpose [8, 9] , rADI particularly derived from M. hominis has the effective of a little dose and an optimum nearer to physiological pH [24] . The purified recombinant protein fractionated on SDS-PAGE under non-reducing conditions revealed a single bond at approximately 50 kDa or inhabited a little dimer (date not shown). Mycoplasma ADI has two cysteine residues in its subunit, but its active form contains neither intermolecular nor intramolecular disulfide bands [26] . ADI is reported to use an active-site cysteine in nucleophilic catalysis of L-arginine degradation [13] . The recombinant protein prepared from inclusion bodies dissolved in guanidine hydrochloride solution depleted with DTT appeared as dimeric protein by SDS-PAGE under non-reducing conditions and native PAGE, but lacked enzyme activity. The recombinant proteins in inclusion bodies may form dimers by disulfide bonds, but the rADI with enzymatic activity may form dimers by another binding except for disulfide bonds. Enzymatic mechanism of ADI is currently unknown and is examined by analyzing crystal structure of ADI [3, 28] .
The specific activity of rADl purified in the present study was lower than that of crude protein of mycoplasmal ADI. Our results indicated that 100 mM PDP solution (pH 7.4) containing L-arginine gave higher activity than 10 mM PDP solution (pH 7.4) with 100 mM L-arginine or 100 mM PDP solution (pH 7.4) without L-arginine in the refolding reaction. Since presence of L-arginine in the refolding reaction markedly increased the enzymatic activity, the reaction intermediates between ADI and L-arginine may be tightly bound by the combination of covalent links, polar interactions, or hydrophobic interactions [3, 5] .
In conclusion, we have obtained a rADI gene encoding an active enzyme, which is inhibitory against human melanoma cells. Further examination may be necessary to raise the enzyme activity for therapeutic purpose. Currently, we are examining spectrum of cancer types other than melanoma, that the ADI is effective. In the future, we will confirm anti-tumor effective of the enzyme and apply it to cancer therapy.
